Hepatic steatosis and liver transplantation

Current Opinion in Organ Transplantation

Volumn 9, Issue 2, 2004, Pages 123-129

  Turgeon, Nicole A ^a   Sollinger, Hans W ^a   Fernandez, Luis A ^a   Musat, Alexandru I ^a   Chin, L Thomas ^a   Kalayoglu, Munci ^a   Knechtle, Stuart J ^a   D'Alessandro, Anthony M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Ischemia reperfusion; Liver; Steatosis; Transplantation

Indexed keywords

EID: 33645638240     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/01.mot.0000127681.70265.bc     Document Type: Review

References (60)

1. D'Alessandro AM, Kalayoglu M, Sollinger HW, et al.: The predictive value of donor liver biopsies on the development of primary nonfunction after orthotopic liver transplantation. Transplant Proc 1991, 23:1536-1537.
2. Adam R, Reynes M, Johann M, et al.: The outcome of steatotic grafts in liver transplantation. Transplant Proc 1991, 23:1538-1540.
3. Todo S, Demetris AJ, Makowka L, et al.: Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989, 47:903-905.
4. Fishbein TM, Fiel MI, Emre S, et al.: Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997, 64:248-251.
5. Chui AK, Shi LW, Rao AR, et al.: Primary graft dysfunction after liver transplantation. Transplant Proc 2000, 32:2219-2220.
6. Loinaz C, Gonzalez EM: Marginal donors in liver transplantation. Hepatogastroenterology 2000, 47:256-263.
7. Markin RS, Wisecarver JL, Radio SJ, et al.: Frozen section evaluation of donor livers before transplantation. Transplantation 1993, 56:1403-1409.
8. Ploeg RJ, D'Alessandro AM, Knechtle SJ, et al.: Risk factors for primary dysfunction after liver transplantation-a multivariate analysis. Transplantation 1993, 55:807-813.
9. Urena MA, Ruiz-Delgado FC, Gonzalez EM, et al.: Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program. Transplant Proc 1998, 30:3288-3291.
10. Briceno J, Solorzano G, Pera C: A proposal for scoring marginal liver grafts. Transpl Int 2000, 13(suppl 1):S249-S252.
11. Rossi M, De Simone P, Peritore D, et al.: Liver transplantation: expanding the donor pool. Transplant Proc 2001, 33:1307-1309.
12. Imber CJ, St Peter SD, Lopez I, et al.: Current practice regarding the use of fatty livers: a trans-Atlantic survey. Liver Transpl 2002, 8:545-549.
13. Yersiz H, Shaked A, Olthoff K, et al.: Correlation between donor age and the pattern of liver graft recovery after transplantation. Transplantation 1995, 60:790-794.
14. Hoofnagle JH, Lombardero M, Zetterman RK, et al.: Donor age and outcome of liver transplantation. Hepatology 1996, 24:89-96.
15. Briceno J, Lopez-Cillero P, Rufian S, et al.: Impact of marginal quality donors on the outcome of liver transplantation. Transplant Proc 1997, 29:477-480.
16. Verran D, Kusyk T, Painter D, et al.: Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003, 9:500-505.
17. Yoo HY, Molmenti E, Thuluvath PJ: The effect of donor body mass index on primary graft nonfunction, retransplantation rate, and early graft and patient survival after liver transplantation. Liver Transpl 2003, 9:72-78.
18. De Carlis L, Giacomoni A, Slim AO, et al.: Factors involved in the functional recovery of a liver graft with particular emphasis on liver steatosis: a multivariate analysis. Transplant Proc 2001, 33:2720-2722.
19. Briceno J, Marchal T, Padillo J, et al.: Influence of marginal donors on liver preservation injury. Transplantation 2002, 74:522-526.
20. Rull R, Vidal O, Momblan D, et al.: Evaluation of potential liver donors: limits imposed by donor variables in liver transplantation. Liver Transpl 2003, 9:389-393.
21. Salizzoni M, Franchello A, Zamboni F, et al.: Marginal grafts: finding the correct treatment for fatty livers. Transpl Int 2003, 16:486-493.
22. Marsman WA, Wiesner RH, Rodriguez L, et al.: Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996, 62:1246-1251.
23. Monsour HP Jr, Wood RP, Ozaki C, et al.: Utility of preoperative liver biopsy in live-related donor patients for liver transplantation. Transplant Proc 1994, 26:138-139.
24. Marcos A, Fisher RA, Ham JM, et al.: Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. Transplantation 2000, 69:1375-1379.
25. Ryan CK, Johnson LA, Germin BI, et al.: One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 2002, 8:1114-1122.
26. Rao AR, Chui AK, Shi LW, et al.: Is donor obesity related to liver steatosis and liver graft dysfunction in liver transplantation? Transplant Proc 2000, 32:2103.
27. Rinella ME, Alonso E, Rao S, et al.: Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl 2001, 7:409-414.
28. Piccinino F, Sagnelli E, Pasquale G, et al.: Complications following percutaneous liver biopsy: a multicentre retrospective study on 68,276 biopsies. J Hepatol 1986, 2:165-173.
29. Marcos A, Fisher RA, Ham JM, et al.: Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000, 69:2410-2415.
30. Chen YS, Cheng YF, De Villa VH, et al.: Evaluation of living liver donors. Transplantation 2003, 75(suppl 3):S16-S19.
31. Freese M, Lyons EA: Ultrasonic backscatter from human liver tissue: its dependence on frequency and protein/lipid composition. J Clin Ultrasound 1977, 5:307-312.
32. Scatarige JC, Scott WW, Donovan PJ, et al.: Fatty infiltration of the liver: ultrasonographic and computed tomographic correlation. J Ultrasound Med 1984, 3:9-14.
33. Lang EM, Lang T, Henne-Bruns D, et al.: Ultrasound investigation prior to organ donation. Transplant Proc 1990, 22:431-432.
34. Rinella ME, McCarthy R, Thakrar K, et al.: Dual-echo, chemical shift gradientecho magnetic resonance imaging to quantify hepatic steatosis: implications for living liver donation. Liver Transpl 2003, 9:851-856.
35. Scott WW Jr, Sanders RC, Siegelman SS: Irregular fatty infiltration of the liver: diagnostic dilemmas. AJR Am J Roentgenol 1980, 135:67-71.
36. Hayashi M, Fujii K, Kiuchi T, et al.: Effects of fatty infiltration of the graft on the outcome of living-related liver transplantation. Transplant Proc 1999, 31:403.
37. Soejima Y, Shimada M, Suehiro T, et al.: Use of steatotic graft in living-donor liver transplantation. Transplantation 2003, 76:344-348.
38. Behrns KE, Tsiotos GG, DeSouza NF, et al.: Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998, 2:292-298.
39. Busuttil RW, Tanaka K: The utility of marginal donors in liver transplantation. Liver Transpl 2003, 9:651-663.
40. Hayashi M, Tokunaga Y, Fujita T, et al.: The effects of cold preservation on steatotic graft viability in rat liver transplantation. Transplantation 1993, 56:282-287.
41. Seifalian AM, Chidambaram V, Rolles K, et al.: In vivo demonstration of impaired microcirculation in steatotic human liver grafts. Liver Transpl Surg 1998, 4:71-77.
42. Seifalian AM, Piasecki C, Agarwal A, et al.: The effect of graded steatosis on flow in the hepatic parenchymal microcirculation. Transplantation 1999, 68:780-784.
43. Sumimoto K, Matsura T, Oku JI, et al.: Protective effect of UW solution on postischemic injury in rat liver: suppression of reduction in hepatic antioxidants during reperfusion. Transplantation 1996, 62:1391-1398.
44. Marni A, Ferrero ME, Gaja G: Metabolic function of grafted liver in rats. Transplantation 1988, 46:830-835.
45. Fukumori T, Ohkohchi N, Tsukamoto S, et al.: Why is fatty liver unsuitable for transplantation? deterioration of mitochondrial ATP synthesis and sinusoidal structure during cold preservation of a liver with steatosis. Transplant Proc 1997, 29:412-415.
46. Rudiger HA, Kang KJ, Sindram D, et al.: Comparison of ischemic preconditioning and intermittent and continuous inflow occlusion in the murine liver.Ann Surg 2002, 235:400-407.
47. Peralta C, Closa D, Xaus C, et al.: Hepatic preconditioning in rats is defined by a balance of adenosine and xanthine. Hepatology 1998, 28:768-773.
48. Clavien PA, Yadav S, Sindram D, et al.: Protective effects of ischemic preconditioning for liver resection performed under inflow occlusion in humans. Ann Surg 2000, 232:155-162.
49. Selzner N, Selzner M, Jochum W, et al.: Ischemic preconditioning protects the steatotic mouse liver against reperfusion injury: an ATP dependent mechanism. J Hepatol 2003, 39:55-61.
50. Connor HD, Gao W, Nukina S, et al.: Evidence that free radicals are involved in graft failure following orthotopic liver transplantation in the rat-an electron paramagnetic resonance spin trapping study. Transplantation 1992, 54:199-204.
51. Mizoe A, Kondo S, Azuma T, et al.: Preventive effects of superoxide dismutase derivatives modified with monosaccharides on reperfusion injury in rat liver transplantation. J Surg Res 1997, 73:160-165.
52. Lehmann TG, Wheeler MD, Froh M, et al.: Effects of three superoxide dismutase genes delivered with an adenovirus on graft function after transplantation of fatty livers in the rat. Transplantation 2003, 76:28-37.
53. Fondevila C, Busuttil RW, Kupiec-Weglinski JW: Hepatic ischemia/reperfusion injury-a fresh look. Exp Mol Pathol 2003, 74:86-93.
54. Amersi F, Farmer DG, Shaw GD, et al.: P-selectin glycoprotein ligand-1 (rPSGL-Ig)-mediated blockade of CD62 selectin molecules protects rat steatotic liver grafts from ischemia/reperfusion injury. Am J Transplant 2002, 2:600-608.
55. Amersi F, Shen XD, Moore C, et al.: Fibronectin-alpha 4 beta 1 integrinmediated blockade protects genetically fat Zucker rat livers from ischemia/reperfusion injury. Am J Pathol 2003, 162:1229-1239.
56. Clavien PA, Camargo CA Jr, Gorczynski R, et al.: Acute reactant cytokines and neutrophil adhesion after warm ischemia in cirrhotic and noncirrhotic human livers. Hepatology 1996, 23:1456-1463.
57. Cressman DE, Greenbaum LE, DeAngelis RA, et al.: Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996, 274:1379-1383.
58. Camargo CA Jr, Madden JF, Gao W, et al.: Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 1997, 26:1513-1520.
59. Sun Z, Klein AS, Radaeva S, et al.: In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology 2003, 125:202-215.
60. Tate J, Olencki T, Finke J, et al.: Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: clinical and laboratory effects. Ann Oncol 2001, 12:655-659.